ClinicalTrials.gg
RecruitingNCT03121404Updated Nov 12, 2026

Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting

An observational study in Cirrhosis, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by The Cleveland Clinic · Observational

How we know

From the registry’s dates

  • Started Nov 2008; still recruiting 18 years later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 415 studies in Fibrosis with a site in United States — 81 open to participants now, 109 under way, 13 of them phase 3. Fibrosis · United States.

Planned enrollment
61st of 84
40 · median 95
Started
2008
with 10 others
Observational
84 of 415
23 open now
Primary completion
2028-12
later than 75 of 108 live
Registered
228th of 415
by date

Among the 415 studies in Fibrosis with a site in United States, this one is the 61st largest by planned enrollment of the 84 observational ones that give a count, is one of 11 that started in 2008, is one of 84 observational ones, reaches primary completion later than 75 of the 108 other live ones, and was the 228th registered.

Fibrosis

1,272 studies on the registry are indexed under Fibrosis; 278 are open to participants now.

Browse Fibrosis studies →

Open to participants now

81 of the 415 studies in Fibrosis with a site in United States are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 197 Fibrosis studies recruiting now, 112 (57%) set no upper age limit and 53 (27%) stop at 75 or younger; 15 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 415 studies in Fibrosis with a site in United States, or all of them as a file.
02

Study summary

Cirrhosis is characterized by loss of muscle as well as fat mass, which increases morbidity and mortality before, during, and after liver transplantation. A common mechanism for the reduced muscle and fat mass in cirrhosis is an increased expression of the TGF (transforming growth factor)beta superfamily member, myostatin, in the muscle and adipose tissue. The present study will examine the expression of myostatin, its receptor and intracellular signaling pathways in the skeletal muscle and mesenteric adipose tissue in cirrhotic patients undergoing liver transplantation as compared to healthy controls undergoing planned abdominal surgery. 16 cirrhotic patients will be identified from the transplant list, and 16 healthy controls from outpatient surgery lists. Nutritional assessment will be performed, including anthropometry (triceps skinfold thickness, mid arm circumference), dual energy x-ray absorptiometry (DEXA), and bioelectrical impedance analysis (BIA). Rectus abdominis muscle tissue and omental fat tissue will be harvested in the operating room, and the expression of signaling proteins involved in skeletal muscle protein synthesis will be quantified. The investigator will also quantify the expression of genes involved in lipolysis and lipid synthesis. The investigator anticipates that the expression of myostatin will be higher in the skeletal muscle and adipose tissue of cirrhotics as compared to controls. There will be a reduction in the expression of the signaling proteins that regulate skeletal muscle protein synthesis, as well as the expression of genes regulating lipogenesis. The increased expression of myostatin will also correlate with reduced anthropometric and DEXA measurements of lean body mass and fat mass.

03

Conditions studied

  • Cirrhosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients will be identified from the Cleveland Clinic transplant list. All subjects with cirrhosis of any etiology who will undergo liver transplantation will make up the group of cirrhosis patients. The controls will be patients without cirrhosis that are undergoing abdominal surgery will be identified from the operating room list at Cleveland Clinic. Rectus abdominis muscle biopsies will be obtained directly after induction of anesthesia for the procedure.

Eligibility criteria

Inclusion Criteria:

  • Age 18-70 years
  • Patients undergoing abdominal surgery (liver transplantation or other surgery)

Control

  1. non liver transplant donor
  2. Elective abdominal surgery (cholecystectomy, diverticulosis, acute gastrointestinal bleeding in the absence of exclusion criteria)

Exclusion Criteria:

  • Exclusion criteria (all subjects)
  • Average daily alcohol intake > 20 g in women and > 30 g in men
  • Diabetes or a fasting serum glucose > 100 mg/dL
  • Hyper- / hypo- thyroidism
  • Renal disease with serum creatinine > 1.4 mg/dL
  • Folate or vitamin B12 deficiency
  • Active intravenous drug use
  • History of bowel surgery or gastric bypass surgery
  • Medications/supplements that affect fat mass or protein mass (creatine, )
  • Pregnancy
  • Chronic diseases that result in cachexia (renal, cardiac, pulmonary, hematologic, cancer)
  • Hepatocellular cancer

Exclusion criteria (controls)

  • Evidence of malnutrition as quantified by triceps skinfold thickness, mid arm muscle area and creatinine height index)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cirrhosis Patient

    Patients will be identified from the transplant list. Inclusion criteria will be all subjects with cirrhosis of any etiology who will undergo liver transplantation. . Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery. For the cirrhotic patients this includes hand grip test and dual energy x-ray absorption (DEXA).

    Procedure: Rectus abdominis muscle biopsy

  • Healthy Controls

    Controls will be identified from the abdominal surgery operating room lists at Cleveland Clinic. Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery which will not include DEXA or hand grip test.

    Procedure: Rectus abdominis muscle biopsy

Interventions

  • ProcedureRectus abdominis muscle biopsy

    Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.

06

What researchers measure

Primary outcomes

  1. Determine the difference in myostatin expression between healthy control and cirrhosis patients

    The primary outcome of this study is to determine the difference in expression of myostatin in skeletal muscle in a one time biopsy of the Rectus abdominis muscle between healthy controls and cirrhotic patients.

    Time frame: 15 minute biopsy

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2008 (actual). Primary completion is estimated for Dec 2028, 241 months after the start.

Of 177 non-industry observational studies under Fibrosis, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 105. This study's planned 241 months is above that.

Counting every sponsor, half of 186 studies reached it within 49 months; a quarter within 22 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2026 → Dec 2028 and completion Dec 2027 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2017
First posted
Apr 20, 2017
StartActual
Nov 14, 2008
Primary completionEst.
Dec 31, 2028was Dec 2026
CompletionEst.
Dec 31, 2029was Dec 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Dec 31, 2028
Nov 12, 2026
Study completion
Dec 31, 2027→Dec 31, 2029
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Dec 31, 2026→Dec 31, 2028
    Study completion Dec 31, 2027→Dec 31, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03121404
Responsible party
Srinivasan Dasarathy (Staff Physician, The Cleveland Clinic) — Principal investigator
First posted
Apr 20, 2017
Start date
Nov 14, 2008
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Annette Bellar, MSLA
Contact
bellara@ccf.org
216-636-5247
Revathi Penumatsa
Contact
penumar@ccf.org

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion